IL-31-Receptor‑α Antagonist Nemolizumab in Treatment‑Refractory Brachioradial Pruritus: A Case Report - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Nemolizumab, an IL-31 Receptor-α Antagonist, for Refractory Brachioradial Pruritus: A Case Report

  • By

  • Manuel P. Pereira

  • Eva M. Grekowitz

  • Martin Metz

  • November 20, 2026

Share

Objective:

To describe the response to nemolizumab in a patient with severe, treatment-refractory brachioradial pruritus (BRP).

Approach:
  • Patient: A 65-year-old woman had more than 4 years of bilateral arm pruritus, burning, and pain, with a positive ice-pack sign and impaired sleep.
  • Prior treatment: Symptoms persisted despite topical therapies, gabapentin, pregabalin, and naltrexone; pregabalin and naltrexone were continued when nemolizumab was started.
  • Nemolizumab and assessment: Treatment began with a 60 mg loading dose followed by 30 mg every 4 weeks. Itch was assessed using the worst itch numerical rating scale (WI-NRS), and quality of life using DLQI and ItchyQoL.
Key Findings:
  • Within 10 days, WI-NRS decreased from 7–9/10 to 3/10 and subsequently was most often 0–1/10.
  • The itch reduction persisted during the 3-month observation period.
  • DLQI and ItchyQoL scores declined markedly after the first dose, indicating improved quality of life.
Interpretation:

The authors report a rapid, sustained antipruritic response and quality-of-life improvement in this patient, while noting that the evidence for biologic therapy in BRP remains limited.

Limitations:
  • This was a single case with concomitant antipruritic treatment.
  • Observation was brief, and clinical photographs were unavailable before and during treatment.
  • The biopsy was performed externally, and histological slides were unavailable for review.
  • Cervical spine imaging was not performed; diabetes and glycemic-control fluctuations may have contributed to pruritus.
Conclusion:

The authors state that nemolizumab may be an option for selected patients with severe, refractory BRP, but additional studies are needed to validate the observation.

Sources:

Original Source(s)

Related Content